Research & publications
Original research is at the heart of what we do. For more than 60 years, our experts have published across a wide range of topics from the fundamentals of health economics itself to the challenges facing health care in the UK and internationally.
The latest research and publications
A global landscape analysis of access to tumour-agnostic therapies
Tumour-agnostic (TA) therapies represent a paradigm shift in oncology by targeting molecular alterations regardless of tumour histology.
Capturing the lived experiences of informal care in acute leukemia
Providing informal care to someone living with acute leukemia imposes a severe multidimensional burden, reshaping relationships and affecting mental health, physical health, career, finances, social activities and more.
The commercial case for investing in ALS
Amyotrophic lateral sclerosis (ALS) is a rare, rapidly progressive neurodegenerative disease with devastating clinical and economic consequences.
The commercial case for investing in ALS
Amyotrophic lateral sclerosis (ALS) is a rare, rapidly progressive…
Achieving Accelerated Patient Access to Cancer Care in Europe
OHE developed the Accelerated Patient Access to Cancer Care in Europe (APACE)…
Patient preferences for treatment in relapsed/refractory acute leukemia
When acute leukemia relapses, treatment decisions can be complex. Patients may…
The value of cell and gene therapies to the UK economy
Cell and gene therapies (CGTs) are moving rapidly from specialist trials to…
The broader economic benefits of COVID-19 vaccination
Extending COVID-19 vaccination eligibility to working-age adults could nearly…
Understanding the preferences of people with acute leukemia for different health outcomes
When we want to understand or measure someone’s “health-related…
Taking STRIDES: The value of diagnostics against AMR
Addressing a critical gap in AMR policy and evaluation Antimicrobial resistance…
Altering the trajectory of HIV in Europe
Despite substantial medical advancements that have transformed HIV into a…
Understanding the Full Value of Long-Acting Therapies: less is more?
Long-acting (LA) therapies represent a significant innovation in pharmaceutical…
An Analysis of NICE’s Optimised Decisions from 2015 to 2024
The National Institute for Health and Care Excellence (NICE) is the body…